Skip to main content

APEC1621M NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations

NCT04284774

NCI-COG Pediatric MATCH (Molecular Analysis for Therapy Choice) - Phase 2 subprotocol of Tipifarnib in Patients with Tumors Harboring HRAS Genomic Alterations

Associated Conditions

Cancer, Multiple Tumor Types

Principal Investigator

Sponsor

Children's Oncology Group

This is a Phase 2 study of a study drug called tipifarnib. The main goal of the study is to find out what effect, good and/or bad effects the study drug tipifarnib may have on your tumor. A second goal of the study is to evaluate side effects that might be caused by tipifarnib, which could shrink your cancer but it could cause side effects.

This study is currently enrolling.